https://www.curiumpharma.com.tr/lutetium-177lu-chloride-nca
Lutetium (177Lu) Chloride n.c.a | Curium
c alutetiumchloridencurium
https://curemydisease.com/studies/safety-study-of-177lu-lnc1004-for-advanced-solid-nct05723640-474
Safety Study of 177Lu-LNC1004 for Advanced Solid NCT05723640
This phase 1 trial tests a new radioactive drug for advanced solid tumors. It aims to check safety and find the right dose for future studies. NCT ID:...
for advancedsafetystudysolid
https://www.thno.org/v16p6132.htm
Integrated radio-theranostics using a [89Zr]Zr-/[177Lu]Lu-labeled B7-H3 antibody-drug conjugate for...
https://medonline.at/news/medizin/10070335/asco-gu-post-docetaxel-therapie-mit-177lu-psma-617/
ASCO GU: Post-Docetaxel-Therapie mit 177Lu-PSMA-617
In einer randomisierten Studie mit 200 Studienteilnehmern wurde 177Lu-PSMA-617 gegen Cabazitaxel verglichen.
asco gupostdocetaxeltherapiemit
https://www.onkomat.pl/22/951/
177Lu-DOTATATE - Varia - program lekowy // Onkomat.pl
program lekowydotatatevariapl
https://www.enets.org/abstract/efficacy-and-safety-of-177lu-lu-edotreotide-vs-everolimus-in-patients-with-grade-1-or-grade-2-gastroenteropancreatic-neuroendocrine-tumours-compete-phase-3-trial.html
Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2...
radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic
https://pmc.ncbi.nlm.nih.gov/articles/PMC9967390/
Radiolysis-Associated Decrease in Radiochemical Purity of 177Lu-Radiopharmaceuticals and Comparison...
The radiolytic degradation of vector molecules is a major factor affecting the shelf life of therapeutic radiopharmaceuticals. The development of time-stable...
associateddecrease
https://biopharmaapac.com/news/80/7006/c-ray-therapeutics-commends-biokin-on-nmpa-approval-for-groundbreaking-177lu-bl-arc001-radiopharmaceutical.html
C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001...
C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001 Radiopharmaceutical